MedTrace Logo

Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

NCT05473624 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2025-04-15

No results posted yet for this study

Summary

This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions

Interventions

DRUG

HRS-1167

Participants will receive HRS-1167.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-23
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05473624 on ClinicalTrials.gov